Summit Therapeutics
SMMT
14 hedge funds and large institutions have $4.76M invested in Summit Therapeutics in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
41% more capital invested
Capital invested by funds: $3.37M → $4.76M (+$1.39M)
27% more funds holding
Funds holding: 11 → 14 (+3)
0% less ownership
Funds ownership: 1.66% → 1.66% (-0%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$37.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$35.8K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$2.71K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.37K |
Top Sellers
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$60.4K |
| 2 |
Morgan Stanley
New York
|
-$22K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LPU
1
Lansdowne Partners (UK)
London,
United Kingdom
| $2.86M | – | – | – |
|
|
PC
2
Polar Capital
London,
United Kingdom
| $537K | -$60.4K | -44,681 | -13% |
|
|
3
Morgan Stanley
New York
| $408K | -$22K | -16,241 | -7% |
|
4
Bank of New York Mellon
New York
| $388K | – | – | – |
|
5
Acadian Asset Management
Boston,
Massachusetts
| $310K | – | – | – |
|
|
6
Renaissance Technologies
New York
| $201K | +$37.3K | +27,576 | +33% |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $47K | +$35.8K | +26,491 | New |
|
|
8
Wells Fargo
San Francisco,
California
| $4K | +$2.71K | +2,000 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $2K | +$1.37K | +1,015 | New |
|
10
Group One Trading
Chicago,
Illinois
| $1K | – | – | – |
|
|
LFG
11
Larson Financial Group
St Louis,
Missouri
| $1K | – | – | – |
|
|
PFBT
12
Parkside Financial Bank & Trust
Saint Louis,
Missouri
| $1K | – | – | – |
|
|
13
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2.3K | -1,700 | -89% |
|
SMMT Hedge Fund Activity: Q3 2019 in Review
14 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2019, worth a combined $4.76M — up 41% from $3.37M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SMMT positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $37.3K. The largest seller was Polar Capital, cutting an estimated $60.4K.
- 14 institutional investors held Summit Therapeutics (SMMT) as of Q3 2019, up from 11 in Q2 2019.
- Funds reported $4.76M of Summit Therapeutics stock for Q3 2019, up 41% quarter-over-quarter.
- 3 funds opened new Summit Therapeutics positions in Q3 2019 and 0 closed out, a net change of +3 holders.
- The largest Summit Therapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $37.3K added.
- The largest Summit Therapeutics seller in Q3 2019 was Polar Capital, an estimated $60.4K sold.
Based on aggregated 13F filings for Q3 2019.